Loading...
•
Jun 30, 2024
Zai Lab Q2 2024 Earnings Report
Achieved impressive commercial growth, maintained financial discipline, and made significant strides across product portfolio.
Key Takeaways
Zai Lab reported a strong second quarter with net product revenue of $100.1 million, representing 45% year-over-year growth. The company saw significant contributions from VYVGART, ZEJULA, and NUZYRA, and is on track to achieve profitability by the end of 2025.
Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth.
VYVGART® (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million.
Three product approvals in China including XACDURO® for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO™ for ROS1+ NSCLC.
Strong balance sheet with a cash position of $730.0 million as of June 30, 2024.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
Zai Lab did not include forward guidance in this report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income